LENZ Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.74) Per Share, William Blair Forecasts (NASDAQ:LENZ)

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Analysts at William Blair issued their Q1 2024 EPS estimates for LENZ Therapeutics in a report issued on Monday, April 15th. William Blair analyst T. Lugo forecasts that the company will post earnings per share of ($0.74) for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for LENZ Therapeutics’ Q2 2024 earnings at ($0.46) EPS, Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.44) EPS, FY2024 earnings at ($2.10) EPS and FY2025 earnings at ($2.95) EPS.

A number of other equities analysts also recently issued reports on the stock. Citigroup started coverage on shares of LENZ Therapeutics in a research note on Wednesday, April 10th. They set a “buy” rating and a $34.00 price objective on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of LENZ Therapeutics in a research note on Monday. Piper Sandler started coverage on shares of LENZ Therapeutics in a research note on Wednesday, March 27th. They set an “overweight” rating and a $28.00 price objective on the stock. Finally, SVB Leerink started coverage on shares of LENZ Therapeutics in a research note on Monday. They set an “outperform” rating and a $32.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, LENZ Therapeutics has an average rating of “Buy” and a consensus price target of $31.33.

LENZ Therapeutics Stock Performance

NASDAQ LENZ opened at $17.70 on Wednesday. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $29.82. The company has a market cap of $147.26 million, a PE ratio of -1.13 and a beta of 0.20.

Insider Activity at LENZ Therapeutics

In other news, Director Ra Capital Management, L.P. bought 998,009 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The stock was bought at an average price of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the transaction, the director now directly owns 3,319,339 shares of the company’s stock, valued at approximately $49,889,665.17. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 38.40% of the stock is currently owned by corporate insiders.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.